RESEARCH TRIANGLE PARK, N.C. – April 22, 2008 – Quintiles Transnational Corp. today announced the appointment of three new practice leaders and a business development head as part of its expanding Quintiles Consulting business, which provides pharmaceutical, biotech and medical device companies with strategic guidance to maximize potential and minimize risk from early discovery through commercialization.
Quintiles Consulting is expanding its current services and building a premier global consulting organization to provide strategic, operational and technical advice to pharmaceutical, biotechnology and medical device companies. The organization will focus on market leading issues and address client needs in three practice areas: Product Development and Commercialization, Regulatory and Quality, and Market Access.
The new leadership team members are:
John J. Doyle, Dr.P.H., M.P.H., Practice Leader, Market Access, U.S. – Doyle leads the U.S. Market Access practice, focusing on market access strategy, health economic assessments, outcomes research, and pricing and reimbursement strategy and support. Doyle will work collaboratively with Dr. Jacco Keja of the Netherlands-based Market Access practice to build the business globally, as well as expand and deepen the group’s service offerings.
Doyle joins Quintiles from Analytica International, a health economics and market access consulting firm he co-founded and led as President. Prior to that, Doyle directed the Oncology and Immunology Economics Research Group at Bristol-Myers Squibb. Since 1993, Doyle has authored more than 50 original research articles, in a variety of therapeutic areas, with a special focus in cardiology, oncology and ophthalmology. He has consulted with global pharmaceutical and biotech firms on strategic concerns regarding product development, pricing, reimbursement, market valuation and other commercialization issues.
Adrian K. McKemey, Ph.D., Practice Leader, Product Development and Commercialization, U.S. – McKemey leads Quintiles Consulting’s Product Development and Commercialization practice, focusing on business transformation, portfolio management, risk partnering, scenario planning and outsourcing strategies.
McKemey was most recently a Principal with the Boston Consulting Group (BCG), working in the Health Care practice and the BCG Strategy Institute. Since 2000, he has helped large pharmaceutical clients optimize product research and development and commercialization through setting strategic direction, developing science policy, reengineering business processes and managing organizational change. Prior to BCG, McKemey was a particle physicist, a tenured faculty member at Brunel University in London and a visiting professor at Stanford University, where he consulted to pharmaceutical and diagnostic companies on commercializing his research.
Jim Featherstone, Ph.D., Practice Leader, Regulatory and Quality and Product Development and Commercialization, Europe – Featherstone will grow the Product Development and Commercialization practice in Europe, as well as oversee and expand the existing regulatory and quality consulting services in Europe.
Featherstone joins Quintiles from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the U.K., where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. Featherstone joined Wood Mackenzie in 2000 to build the life sciences strategic consulting practice, defining the overall strategy and executing growth in the European and U.S. markets. Prior to this, Featherstone was with the pharmaceutical division of British Petroleum, which he joined after a distinguished academic career.
Matt Eberhart, MBA, Vice President, Business Development – Eberhart is responsible for establishing a global business development framework, leading the business development efforts in the U.S. and serving as the internal liaison to the broader Quintiles organization.
Eberhart has worked with a number of emerging professional services companies in the life sciences industry, building and managing sales and marketing organizations. Previously, Eberhart was an executive management team member at Katalyst, a privately held venture capital and advisory firm. He has also served as a Senior Manager and European Leadership Team member for Deloitte Consulting's Life Sciences Practice.
Each new member of the team brings strong consulting practice-building skills, entrepreneurial capabilities and deep life sciences industry knowledge,” said Jay Norman, President of Quintiles Consulting. “Quintiles is well positioned to become the premier global provider of strategic consulting to the life sciences industry.”
About Quintiles Consulting
Quintiles Consulting works with pharmaceutical, biotech and medical device companies to maximize potential and minimize risk from discovery through development and commercialization by providing expert strategic, operational and technical advice. Building on the global reach and expertise of Quintiles Transnational, Quintiles Consulting practice areas include Product Development and Commercialization, Regulatory and Quality, and Market Access. Quintiles Consulting has full-time consultants based across the U.S. and Europe to serve its global clients. For more information, please visit www.quintiles.com/consulting.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With more than 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at www.quintiles.com.